Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
About this trial
The goal of this observational study is to learn about the role of biomarkers in spontaneous subarachnoid hemorrhage (sSAH) as predictors of severity of clinical outcome. The test of biomarkers is based on regular blood and urinary samples. Blood levels of highly specific cardiac troponin (cTNI), natriuretic peptides (NT-ProBNP), S100 beta protein, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase (UCH-L1), soluble Tumor Necrosis Factor Receptor-2 (sST2), and soluble urokinase plasminogen activator receptor (suPAR), as well as urinary levels of epinephrine and norepinephrine are the biomarkers explored. All adult participants with spontaneous subarachnoid hemorrhage are involved in the study.
The main questions aim to answer are:
* which of these molecules can be prognostic for patients' outcome * which are the prognostic levels of these biomarkers to predict patients' outcome.
Participants will undergo blood and urinary samples during hospitalization at 24 hours, 72 hours and after 7 days.
Eligibility criteria
Qualifiers
Patients with spontaneous subarachnoid hemorrhage, including those with perimesencephalic subarachnoid hemorrhage and aneurysmal subarachnoid hemorrhage.
Adult patients.
Confirmed presence of spontaneous subarachnoid hemorrhage through neuroimaging.
Obtained informed consent for specific study biomarkers
Disqualifiers
Age <18 years.
Post-traumatic subarachnoid hemorrhage.
Trial design
Treatments tested in this trial
- biomarkers
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov